Compare ClearPoint Neuro Inc (CLPT) vs Flux Power Holdings Inc (FLUX) Price & Performance

ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.

Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.

FLUX trades at $0.7304, down 5.94% in the last session, with a bearish technical signal from moving averages. The company reported mixed quarterly results, missing Q3 2026 EPS estimates but beating in Q4 2025. Revenue declined from $66M in 2025 to $51M in 2026, with negative net income margins persisting. Recent developments include the launch of SkyEMS 3.0 AI-powered fleet management software and new executive appointments aimed at growth acceleration.

Despite unanimous analyst buy ratings, FLUX faces significant profitability challenges with negative ROE and ROA. The stock's primary investment opportunity lies in its clean energy technology positioning and strong analyst support, but risks include ongoing losses, revenue contraction, and competitive pressures in the energy storage market that could limit near-term upside potential.